Danaher Corporation (DHR)
Coverage summary
Aardvark Labs Capital Research has covered Danaher Corporation (DHR) since July 23, 2025. The company is in the Healthcare sector. This page lists 6 reports: 6 earnings recaps.
The latest is the Q3 2026 Earnings Recap, published October 25, 2026. That report moved the rating from Outperform to Hold. The rating has changed twice since coverage began.
Translations: 5 in Chinese.
Rating history
All DHR reports
Recap: Q3 2026
Core Accelerates and a New CEO Sets the Agenda, but the Discount Is Gone: Downgrading Danaher to Hold
Recap: Q2 2026
Core Accelerates and Life Sciences Breaks Out, but a Bioprocessing Shipment Push-Out Sinks the Stock 11% — Maintaining Outperform
Recap: Q1 2026
Equipment Orders Inflect +30%, EPS Beats and the Guide Rises, and Masimo Reloads the M&A Engine — Maintaining Outperform
Recap: Q4 2025
Equipment Turns the Corner and FY25 Hits the High End; a Confirm-Not-Beat 2026 Guide Cools a Run-Up — Maintaining Outperform
Recap: Q3 2025
Core Reaccelerates, Margins Expand, and a Constructive 2026 Lands: Upgrading Danaher to Outperform
Recap: Q2 2025
The Bioprocessing Recovery Is Real, the Core Is Still Slow: Initiating Danaher at Hold